SMARCA4 and lung cancer: High-risk patients had a significantly higher prevalence of TP53 and SMARCA4 alterations, which were both demonstrated to be risk biomarkers associated with worse survival in lung cancer patients (Jiao et al., 2018; Schoenfeld et al., 2020).